These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 20538861)

  • 21. Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41.
    Gustchina E; Li M; Louis JM; Anderson DE; Lloyd J; Frisch C; Bewley CA; Gustchina A; Wlodawer A; Clore GM
    PLoS Pathog; 2010 Nov; 6(11):e1001182. PubMed ID: 21085615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.
    Montgomery DL; Wang YJ; Hrin R; Luftig M; Su B; Miller MD; Wang F; Haytko P; Huang L; Vitelli S; Condra J; Liu X; Hampton R; Carfi A; Pessi A; Bianchi E; Joyce J; Lloyd C; Geleziunas R; Bramhill D; King VM; Finnefrock AC; Strohl W; An Z
    MAbs; 2009; 1(5):462-74. PubMed ID: 20065653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crystal structure of a 3B3 variant--a broadly neutralizing HIV-1 scFv antibody.
    Clark KR; Walsh ST
    Protein Sci; 2009 Dec; 18(12):2429-41. PubMed ID: 19785005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization.
    Willis JR; Finn JA; Briney B; Sapparapu G; Singh V; King H; LaBranche CC; Montefiori DC; Meiler J; Crowe JE
    Proc Natl Acad Sci U S A; 2016 Apr; 113(16):4446-51. PubMed ID: 27044078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.
    Prabakaran P; Gan J; Wu YQ; Zhang MY; Dimitrov DS; Ji X
    J Mol Biol; 2006 Mar; 357(1):82-99. PubMed ID: 16426633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
    Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120.
    Spurrier B; Sampson JM; Totrov M; Li H; O'Neal T; Williams C; Robinson J; Gorny MK; Zolla-Pazner S; Kong XP
    Structure; 2011 May; 19(5):691-9. PubMed ID: 21565703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.
    Klein F; Diskin R; Scheid JF; Gaebler C; Mouquet H; Georgiev IS; Pancera M; Zhou T; Incesu RB; Fu BZ; Gnanapragasam PN; Oliveira TY; Seaman MS; Kwong PD; Bjorkman PJ; Nussenzweig MC
    Cell; 2013 Mar; 153(1):126-38. PubMed ID: 23540694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.
    Zwick MB; Komori HK; Stanfield RL; Church S; Wang M; Parren PW; Kunert R; Katinger H; Wilson IA; Burton DR
    J Virol; 2004 Mar; 78(6):3155-61. PubMed ID: 14990736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.
    Cale EM; Gorman J; Radakovich NA; Crooks ET; Osawa K; Tong T; Li J; Nagarajan R; Ozorowski G; Ambrozak DR; Asokan M; Bailer RT; Bennici AK; Chen X; Doria-Rose NA; Druz A; Feng Y; Joyce MG; Louder MK; O'Dell S; Oliver C; Pancera M; Connors M; Hope TJ; Kepler TB; Wyatt RT; Ward AB; Georgiev IS; Kwong PD; Mascola JR; Binley JM
    Immunity; 2017 May; 46(5):777-791.e10. PubMed ID: 28514685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural and genetic basis for development of broadly neutralizing influenza antibodies.
    Lingwood D; McTamney PM; Yassine HM; Whittle JR; Guo X; Boyington JC; Wei CJ; Nabel GJ
    Nature; 2012 Sep; 489(7417):566-70. PubMed ID: 22932267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement in affinity and HIV-1 neutralization by somatic mutation in the heavy chain first complementarity-determining region of antibodies triggered by HIV-1 infection.
    Torán JL; Sánchez-Pulido L; Kremer L; del Real G; Valencia A; Martínez-A C
    Eur J Immunol; 2001 Jan; 31(1):128-37. PubMed ID: 11169446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design.
    Kwon YD; Georgiev IS; Ofek G; Zhang B; Asokan M; Bailer RT; Bao A; Caruso W; Chen X; Choe M; Druz A; Ko SY; Louder MK; McKee K; O'Dell S; Pegu A; Rudicell RS; Shi W; Wang K; Yang Y; Alger M; Bender MF; Carlton K; Cooper JW; Blinn J; Eudailey J; Lloyd K; Parks R; Alam SM; Haynes BF; Padte NN; Yu J; Ho DD; Huang J; Connors M; Schwartz RM; Mascola JR; Kwong PD
    J Virol; 2016 Jul; 90(13):5899-5914. PubMed ID: 27053554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic.
    Euler Z; Bunnik EM; Burger JA; Boeser-Nunnink BD; Grijsen ML; Prins JM; Schuitemaker H
    J Virol; 2011 Jul; 85(14):7236-45. PubMed ID: 21561918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determinants in V2C2 region of HIV-1 clade C primary envelopes conferred altered neutralization susceptibilities to IgG1b12 and PG9 monoclonal antibodies in a context-dependent manner.
    Patil S; Choudhary I; Chaudhary NK; Ringe R; Bansal M; Shukla BN; Boliar S; Chakrabarti BK; Bhattacharya J
    Virology; 2014 Aug; 462-463():266-72. PubMed ID: 24999839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Germlining of the HIV-1 broadly neutralizing antibody domain m36.
    Chen W; Li W; Ying T; Wang Y; Feng Y; Dimitrov DS
    Antiviral Res; 2015 Apr; 116():62-6. PubMed ID: 25676867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1.
    Morgand M; Bouvin-Pley M; Plantier JC; Moreau A; Alessandri E; Simon F; Pace CS; Pancera M; Ho DD; Poignard P; Bjorkman PJ; Mouquet H; Nussenzweig MC; Kwong PD; Baty D; Chames P; Braibant M; Barin F
    J Acquir Immune Defic Syndr; 2016 Mar; 71(3):237-45. PubMed ID: 26413851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.
    Ofek G; Tang M; Sambor A; Katinger H; Mascola JR; Wyatt R; Kwong PD
    J Virol; 2004 Oct; 78(19):10724-37. PubMed ID: 15367639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies.
    Mouquet H; Scharf L; Euler Z; Liu Y; Eden C; Scheid JF; Halper-Stromberg A; Gnanapragasam PN; Spencer DI; Seaman MS; Schuitemaker H; Feizi T; Nussenzweig MC; Bjorkman PJ
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):E3268-77. PubMed ID: 23115339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.